Table 5.
Summary of previous studies for hypo-fractionation re-RT in locally recurrent nasopharyngeal cancer patients, and comparison with the outcomes of the current study
| No. of patients | 1st RT modality | Re-RT modality | Total dose for re-RT (Gy) | Fraction size for re-RT (Gy) | Survival | Major morbidity | |
|---|---|---|---|---|---|---|---|
| Lee et al. (2000) [19] | 487 | 2D RT | 2D RT | 45.6 (7.5–70) | 3 (1.8–5) | 5-Year OS, 12% | 5-Year TFS, 48% |
| Ng et al. (2020) [7] | 91 | IMRT | 3D RT, 1.1% IMRT, 83.5% SBRT, 15.4% |
60 (45–70) | 1.2 (bid), 19.8% 1.8–2.5, 63.7% > 2.5, 16.5% |
2-Year OS, 59.6% | 18.7% |
| Tian et al. (2014) [20] | 58 | IMRT, 1.7% | IMRT | 60 | 2.2 | 5-Year OS, 42.2% | 28.8% |
| Hu et al. (2018) [16] | 75 | IMRT, 96% | Carbon ion therapy | 50–66 | 2–3 | 1-Year OS, 98.1% | Grade 3–4, 11.9% |
| Leung et al. (2009) [21] | 30 | 2D/3D RT | SBRT | 54 (32–57) | 3 (2.5–4.5) | 5-Year LFFS, 56.8% 5-Year OS, 40% |
5-Year major TFS, 21.4% |
| Ozyigit et al. (2011) [22] | 24 | N/A | SBRT (Cyberknife) | 30 | 6 | 2-Year CSS, 64% 2-Year LFFS, 82% |
12.5% |
| Seo et al. (2009) [23] | 35 | N/A | SBRT (Cyberknife) | 24~45 | 7.5–12 | 5-Year OS, 60% | Grade 4–5, 6% |
| Current study | 60 | 2D/3D RT 51.7% IMRT, 48.3% |
3D RT, 33.3% IMRT/IMPT, 66.7% |
60 (40–70) | 3.0 (2.3–4.0) | 5-Year LFFS, 52.5% 5-Year OS, 45.8% |
5-Year grade ≥ 3 TFS, 84.7% Grade 5, 13.1% |
2D/3D RT, 2-/3-dimensional radiation therapy; bid, twice per day; CSS, cancer-specific survival; IMPT, intensity-modulated proton therapy; IMRT, intensity-modulated radiation therapy; LFFS, local failure-free survival; N/A, not available; OS, overall survival; RT, radiation therapy; SBRT, stereotactic body radiation therapy; TFS, toxicity-free survival.